| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $23,618 | 6 | 100 |
Sells | $0 | 0 | 0 |
| Equels Thomas K | CEO & President | 6 | $23,618 | 0 | $0 | $23,618 |
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, …
Over the last 12 months, insiders at AIM ImmunoTech Inc. have bought $23,618 and sold $0 worth of AIM ImmunoTech Inc. stock.
On average, over the past 5 years, insiders at AIM ImmunoTech Inc. have bought $121,986 and sold $884 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Equels Thomas K (CEO & President) — $23,618.
The last purchase of 31,675 shares for transaction amount of $5,068 was made by Equels Thomas K (CEO & President) on 2026‑10‑23.
| 2026-10-23 | Equels Thomas K | CEO & President | 31,675 0.1894% | $0.16 | $5,068 | +3.01% | ||
| 2026-10-22 | Equels Thomas K | CEO & President | 31,250 0.0793% | $0.16 | $5,094 | -0.09% | ||
| 2026-09-17 | Equels Thomas K | CEO & President | 24,000 0.675% | $0.21 | $4,992 | -20.16% | ||
| 2026-09-16 | Equels Thomas K | CEO & President | 11,000 0.3201% | $0.21 | $2,310 | -17.81% | ||
| 2026-09-15 | Equels Thomas K | CEO & President | 22,000 0.6688% | $0.22 | $4,862 | -18.07% | ||
| 2026-09-14 | Equels Thomas K | CEO & President | 5,900 0.0339% | $0.22 | $1,292 | -20.95% | ||
| 2025-06-13 | Equels Thomas K | CEO & President | 107 0.0097% | $7.70 | $824 | -78.49% | ||
| 2025-06-12 | Equels Thomas K | CEO & President | 103 0.0105% | $8.70 | $896 | -82.76% | ||
| 2025-04-11 | Equels Thomas K | CEO & President | 1.97M 0.5876% | $0.03 | $50,000 | -15.25% | ||
| 2025-04-11 | KELLNER TED D | director | 1.97M 0.5876% | $0.03 | $50,000 | -15.25% | ||
| 2025-04-11 | MITCHELL WILLIAM M | director | 196,851 0.0588% | $0.03 | $5,000 | -15.25% | ||
| 2025-04-04 | Equels Thomas K | CEO & President | 41,000 0.0304% | $0.06 | $2,583 | -71.43% | ||
| 2025-04-04 | Rodino Peter W III | COO, Secretary, Gen. Counsel | 500 0.0005% | $0.09 | $44 | -71.43% | ||
| 2025-03-05 | Equels Thomas K | CEO & President | 50,000 0.0738% | $0.13 | $6,730 | -79.72% | ||
| 2025-03-04 | Equels Thomas K | CEO & President | 127,334 0.1794% | $0.12 | $15,060 | -77.95% | ||
| 2024-12-19 | Sale | MITCHELL WILLIAM M | director | 4,580 0.0071% | $0.19 | $884 | -62.64% | |
| 2024-12-18 | Equels Thomas K | CEO & President | 22,727 0.035% | $0.21 | $4,682 | -62.01% | ||
| 2024-12-02 | APPELROUTH STEWART | director | 11,112 0.0168% | $0.21 | $2,356 | -61.86% | ||
| 2024-11-21 | Equels Thomas K | CEO & President | 20,000 0.0331% | $0.21 | $4,240 | -58.48% | ||
| 2024-11-20 | Equels Thomas K | CEO & President | 145,110 0.2237% | $0.19 | $27,915 | -56.00% |
| Equels Thomas K | CEO & President | 189747 0.4756% | $30,492.34 | 55 | 0 | <0.0001% |
| KELLNER TED D | director | 1969504 4.9367% | $316,499.29 | 1 | 0 | |
| CARTER WILLIAM A | CEO | 1225585 3.072% | $196,951.51 | 9 | 2 | |
| MITCHELL WILLIAM M | director | 521723 1.3077% | $83,840.89 | 3 | 1 | |
| Rodino Peter W III | COO, Secretary, Gen. Counsel | 401762 1.0071% | $64,563.15 | 6 | 0 | <0.0001% |
| APPELROUTH STEWART | director | 355509 0.8911% | $57,130.30 | 10 | 0 | <0.0001% |
| Bernhardt Charles Thomas III | Chief Financial Officer | 265214 0.6648% | $42,619.89 | 2 | 1 | |
| Lander Russel J | VP of Process/QualityAssurance | 207983 0.5213% | $33,422.87 | 4 | 0 | |
| SPENCE STEVEN D | director | 167870 0.4208% | $26,976.71 | 6 | 0 | |
| PIANI RICHARD | director | 102861 0.2578% | $16,529.76 | 2 | 0 | |
| ETHERIDGE RANSOM | director | 94430 0.2367% | $15,174.90 | 1 | 0 | |
| PASCALE ADAM | CFO | 59648 0.1495% | $9,585.43 | 3 | 0 | |
| BRYAN NANCY | director | 38462 0.0964% | $6,180.84 | 1 | 0 | <0.0001% |
| SPRINGATE WAYNE S | Sr. VP of Operations | 8672 0.0217% | $1,393.59 | 6 | 1 | |
| PETERSON ROBERT E | Chief Financial Officer | 8000 0.0201% | $1,285.60 | 1 | 0 | |
| STRAYER DAVID R | Chief Science/Medical Officer | 5420 0.0136% | $870.99 | 10 | 2 | |
| Bonelli Anthony | President & COO | 2500 0.0063% | $401.75 | 1 | 0 | |
| Dickey Robert IV | Senior Vice President | 2500 0.0063% | $401.75 | 1 | 0 |
$13,664,154 | 40 | -70.35% | $7.05M | |
$29,645,465 | 28 | 8.09% | $6.48M | |
$63,749,694 | 24 | -12.24% | $6.4M | |
$287,718 | 15 | -41.45% | $5.68M | |
$1,246,170 | 12 | 65.67% | $5.42M |
| Increased Positions | 7 | +50% | 27,675 | +25.78% |
| Decreased Positions | 4 | -28.57% | 28,948 | -26.96% |
| New Positions | 2 | New | 126 | New |
| Sold Out Positions | 4 | Sold Out | 28,948 | Sold Out |
| Total Postitions | 17 | +21.43% | 106,086 | -1.19% |